prikaz prve stranice dokumenta Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice
  Download
PDF 612.16 KB
Scientific paper - Original scientific paper
Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice
Pathology and Oncology Research, 27 (2021); 1609963. https://doi.org/10.3389/pore.2021.1609963
Čerina, Dora; Matković, Višnja; Katić, Kristina; Belac Lovasić, Ingrid; Šeparović, Robert; Canjko, Ivana; Jakšić, Blanka; Fröbe, Ana; Pleština, Stjepko; Bajić, Žarko; Vrdoljak, Eduard

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Čerina, D., Matković, V., Katić, K., Belac Lovasić, I., Šeparović, R., Canjko, I. ... Vrdoljak, E. (2021). Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. Pathology and Oncology Research, 27.. doi: 10.3389/pore.2021.1609963

Čerina, Dora, et al. "Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice." Pathology and Oncology Research, vol. 27, 2021. https://doi.org/10.3389/pore.2021.1609963

Čerina, Dora, Višnja Matković, Kristina Katić, Ingrid Belac Lovasić, Robert Šeparović, Ivana Canjko, Blanka Jakšić, et al. "Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice." Pathology and Oncology Research 27 (2021). https://doi.org/10.3389/pore.2021.1609963

Čerina, D., et al. (2021) 'Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice', Pathology and Oncology Research, 27. doi: 10.3389/pore.2021.1609963

Čerina D, Matković V, Katić K, Belac Lovasić I, Šeparović R, Canjko I, and sur.. Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. Pathology and Oncology Research [Internet]. 2021 September 27 [cited 2024 November 22];27. doi: 10.3389/pore.2021.1609963

D. Čerina, et al., "Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice", Pathology and Oncology Research, vol. 27, September 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:777032. [Accessed: 22 November 2024]

Metadata
Title (english)Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice
AuthorDora Čerina
AuthorVišnja Matković
AuthorKristina Katić
AuthorIngrid Belac Lovasić
AuthorRobert Šeparović
AuthorIvana Canjko
AuthorBlanka Jakšić
AuthorAna Fröbe
AuthorStjepko Pleština
AuthorŽarko Bajić
AuthorEduard Vrdoljak
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathophysiology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathophysiology
Abstract (english)
Comprehensive genomic profiling (CGP) is gradually becoming an inevitable part of the everyday oncology clinical practice. The interpretation and optimal implementation of the results is one of the hot topics of modern-day oncology. According to the recent findings, uterine cancer harbors a high level of gene alterations but is still insufficiently explored. The primary goal of this project was to assess the proportion of patients with targetable mutations. Also, the aim was to define and emphasize potential opportunities as well as the problems we have faced in the first year of testing on the national level. We performed a multicentric, retrospective, nested cross-sectional analysis on the total population of Croatian patients with advanced/metastatic uterine cancer where the tumor CGP was performed during 2020. CGP of the tumor tissue of 32 patients revealed clinically relevant genomic alterations (CRGA) in 27 patients (84%) with a median of 3 (IQR 1-4) CRGA per patient. The most common CRGAs were those of phosphatide-inositol-3 kinases (PIK3) in 22 patients (69%), with 13/22 (59%) of those patients harboring PIK3CA mutation. The next most common CGRAs were ARID1A and PTEN mutations in 13 (41%) and 11 (34%) patients, respectively. Microsatellite status was determined as stable in 21 patients (66%) and highly unstable in 10 patients (31%). A high tumor mutational burden (≥10Muts/Mb) was reported in 12 patients (38%). CGP analysis reported some kind of targeted therapy for 28 patients (88%). CGP determined clinically relevant genomic alterations in the significant majority of patients with metastatic uterine cancer, defining it as a rich ground for further positioning and development of precision oncology.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titlePathology and Oncology Research
Numberingvol. 27, 1609963
e-ISSN1532-2807
DOIhttps://doi.org/10.3389/pore.2021.1609963
URN:NBNurn:nbn:hr:105:777032
Publication2021-09-27
Document URLhttps://www.por-journal.com/articles/10.3389/pore.2021.1609963/full
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-04-07 08:04:43